New England Private Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

New England Private Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-15,554	Closed	-$17K	–	121
2016 Q3	$17K	Hold	15,554	–	–	0.01%	123
2016 Q2	$11K	Hold	15,554	–	–	﹤0.01%	119
2016 Q1	$18K	Hold	15,554	–	–	0.01%	118
2015 Q4	$38K	Hold	15,554	–	–	0.02%	121
2015 Q3	$47K	Buy	+15,554	New	+$67.1K	0.02%	108

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

TCM

Tanaka Capital Management New York $59.9M AUM

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

New England Private Wealth Advisors's CPRX Position: Q4 2016 in Review

New England Private Wealth Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q4 2016, closing a stake of 15,554 shares — an estimated $17K sold.

New England Private Wealth Advisors first reported a position in CPRX in Q3 2015 and held it in 5 quarters. The position peaked at $47K in Q3 2015. 54 funds tracked by Wall St. Rank hold CPRX as of Q4 2016.

New England Private Wealth Advisors reported no remaining Catalyst Pharmaceutical position as of Q4 2016 after selling out during the quarter.
New England Private Wealth Advisors sold 15,554 Catalyst Pharmaceutical shares in Q4 2016, an estimated $17K.
New England Private Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q3 2015 and held it in 5 quarters.
New England Private Wealth Advisors's Catalyst Pharmaceutical position peaked at $47K in Q3 2015.
54 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2016.

Based on New England Private Wealth Advisors's 13F filing for Q4 2016, filed 9 Feb 2017.